Takeda and Amylin formally end rocky global alliance for obesity
This article was originally published in Scrip
Executive Summary
Takeda and Amylin Pharmaceuticals have decided formally to end their October 2009 global agreement for the co-development and co-commercialization of compounds for obesity.
You may also be interested in...
Norgine Holds Out Cetilistat Hope As Takeda Alliance Ends In Challenging Japan Market
Takeda and Norgine’s decision to finally end their alliance for cetilistat in Japan, years after the obesity drug was approved in its first potential market, serves as another sign of the sector’s challenges in the country.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.